By Nate Media Health, 1/17/2024
Scabies, a highly contagious parasitic skin disease caused by the Sarcoptes scabiei mite, is experiencing a concerning resurgence across Europe, with the UK particularly grappling with a shortage of effective treatments. Dermatology specialist in Manchester have warned that the scarcity of available treatments exacerbates the situation, especially during the winter months when people spend more time together indoors.
Despite being a widespread condition, scabies cases in England are surpassing typical levels, with outbreaks reported in care homes and university accommodations, especially in the northern regions. Recent surveillance reports indicate 1,926 cases across the country between early December and January.
The surge in cases is part of a decade-long trend, not attributed to climate change but linked to treatment shortages, treatment failures, and persistent social stigma surrounding the disease. Scabies mites, left untreated, reproduce and cause continuous itching cycles, easily spreading through skin-to-skin contact, such as during sexual activity.
The primary treatments, permethrin and malathion, are lotions requiring thorough application across the entire body. However, recent studies show a growing treatment failure rate, potentially reaching 30 percent, with concerns about emerging drug resistance among the mites.
Jo Middleton, a research fellow, emphasizes the difficulty of eradicating outbreaks, citing challenges in decontaminating bedding and furniture. The cumbersome application of permethrin adds to the problem, leading to failures and ongoing infections.
In addition to treatment challenges, the UK faces a severe shortage of scabies medications, attributed to pandemic-related supply chain issues and Brexit-related import problems. Paula Geanau from the British Association of Dermatologists explains that any stock reaching the UK is quickly depleted due to the high demand.
Researchers advocate for increased surveillance of potential scabies outbreaks, highlighting the risk of secondary skin infections from streptococcus and staphylococcal bacteria, especially in vulnerable populations like those in care homes.
Scabies, often neglected due to stigma, is not solely confined to certain populations, as previously suggested. Misinformation surrounding the disease has also affected the use of ivermectin, an effective oral medication widely used in the global south. Despite its proven efficacy in treating scabies, false claims regarding its effectiveness against COVID-19 have hindered its adoption in the UK.
Doctors, including Naveed Ijaz a dermatology expert, urge for more effective public health campaigns to manage the current outbreak in the UK. They emphasize the importance of educating the public about post-treatment itching, which can be mistaken for a recurrence of scabies, leading to unnecessary use of permethrin and further exacerbating shortages.
As the UK grapples with the scabies resurgence, the need for comprehensive public health strategies, increased medication supply, and accurate information dissemination becomes paramount to effectively combat this contagious skin condition.
